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Objectives: Extracorporeal membrane oxygenation provides shortterm cardiopulmonary life support, but is associated with peripheral innate inflammation, disruptions in cerebral autoregulation,
and acquired brain injury. We tested the hypothesis that extracorporeal membrane oxygenation also induces CNS-directed
adaptive immune responses which may exacerbate extracorporeal
membrane oxygenation-associated brain injury.
Design: A single center prospective observational study.
Setting: Pediatric and cardiac ICUs at a single tertiary care, academic center.
Patients: Twenty pediatric extracorporeal membrane oxygenation
patients (0–14 yr; 13 females, 7 males) and five nonextracorporeal membrane oxygenation Pediatric Logistic Organ Dysfunction
score matched patients
Interventions: None.
Measurements and Main Results: Venous blood samples were
collected from the extracorporeal membrane oxygenation circuit
at day 1 (10–23 hr), day 3, and day 7 of extracorporeal membrane oxygenation. Flow cytometry quantified circulating innate
and adaptive immune cells, and CNS-directed autoreactivity was
detected using an in vitro recall response assay. Disruption of cerebral autoregulation was determined using continuous bedside
near-infrared spectroscopy and acquired brain injury confirmed
by MRI. Extracorporeal membrane oxygenation patients with acquired brain injury (n = 9) presented with a 10-fold increase in
interleukin-8 over extracorporeal membrane oxygenation patients
without brain injury (p < 0.01). Furthermore, brain injury within
extracorporeal membrane oxygenation patients potentiated an
inflammatory phenotype in adaptive immune cells and selective
autoreactivity to brain peptides in circulating B cell and cytotoxic
T cell populations. Correlation analysis revealed a significant relationship between adaptive immune responses of extracorporeal
membrane oxygenation patients with acquired brain injury and
loss of cerebral autoregulation.
Conclusions: We show that pediatric extracorporeal membrane
oxygenation patients with acquired brain injury exhibit an induction
of pro-inflammatory cell signaling, a robust activation of adaptive
immune cells, and CNS-targeting adaptive immune responses. As
these patients experience developmental delays for years after exMarch 2019 • Volume 47 • Number 3
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tracorporeal membrane oxygenation, it is critical to identify and
characterize adaptive immune cell mechanisms that target the developing CNS. (Crit Care Med 2019; 47:e206–e213)
Key Words: autoreactivity; B cells; cerebral autoregulation;
cytotoxic T cells; extracorporeal membrane oxygenation; helper T
cells

E

xtracorporeal membrane oxygenation (ECMO) is a complex technique that provides life support during severe
respiratory and/or cardiac failure (1). The expanded use
of ECMO in pediatric patients reveals a number of complications, including an acute induction of systemic inflammatory
response syndrome (SIRS), long-term neurodevelopmental
deficits, and an increasing number of children exhibiting neurologic morbidities (1, 2). In fact, acquired neurologic injury is
a significant risk factor, secondary to detrimental mechanisms
associated with the underlying disease that contributes to both
morbidity and mortality in patients on ECMO (3).
ECMO circuits expose blood to artificial surfaces and activate the coagulation and complement systems (4). This can
induce a robust innate (i.e., primary) immune response, that
is, similar to SIRS (5). Additionally, ECMO increases the production of interleukin (IL)–1β, IL-6, IL-8, IL-10, and tumor necrosis factor-α within hours of initiation (5). Complement and
pro-inflammatory cytokines activate neutrophils and promote
migration into target organs (e.g., lungs) which further exacerbate pathology (6, 7). Similarly, monocytes are also activated by
ECMO, although their activation rate is much slower (8). The
contribution of adaptive immunity during ECMO neuropathology, however, remains unstudied despite the contribution
of adaptive immune mechanisms to similar inflammatory neurologic diseases (9). ECMO promotes cytokine production and
precipitates disruptions in cerebral blood flow (CBF) which facilitate CNS antigen release into the periphery—both necessary
steps to CNS-directed adaptive immunity. Thus, the primary
objective of this pilot study is to test the hypothesis that ECMO
initiates CNS-targeting adaptive immunity that may contribute
to long-term ECMO-induced neurologic injury.

MATERIALS AND METHODS
Human Subjects
This is a prospective pilot observational study in patients (0–18
yr old) who underwent venoarterial and venovenous ECMO in
pediatric and cardiac ICUs at Children’s Health (Supplemental
Table 1, Supplemental Digital Content 1, http://links.lww.
com/CCM/E238; exclusions are shown in Fig. 1). The study
was approved by the University of Texas Southwestern Medical Center Institutional Review Board. Healthy control plasma
samples were obtained from volunteers (STU122013-036). Sick
control patients who were Pediatric Logistic Organ Dysfunction (PELOD) score matched were also enrolled (Supplemental
Table 2, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). Demographic, clinical, laboratory, imaging, and
Critical Care Medicine

outcome data were obtained from the medical chart for each
subject. Routine brain MRI was done for most patients after
ECMO. Brain injury was defined as abnormal brain MRI findings with or without clinical correlation, as determined by
a licensed neuroradiologist, with images as standard of care
and not specifically collected for this project. All patients were
placed on Rotaflow centrifugal pumps, cannulation for venoarterial was through carotid artery and internal jugular vein and
for venovenous through double lumen cannulas placed in the
right internal jugular vein. Heparin was the anticoagulation of
choice. All patients were sedated with fentanyl and versed, and
dexmedetomidine was used as an adjunct in some patients.
Study Design
At the bedside, cerebral autoregulation measurements were
collected over the course of ECMO. Bedside blood draws were
collected on day 1 (within 10–23 hr of cannulation), day 3, and
day 7 of ECMO. Blood was processed for an immediate leukocyte survey by flow cytometry (gating shown in Supplemental
Fig. 2, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). Plasma and immune cells were additionally
banked for enzyme-linked immunosorbent assay (ELISA) and
autoimmune assay, with all time points of each patient assayed
concurrently.
For detailed methodologies pertaining to peripheral blood
mononuclear cells flow cytometry, carboxyfluoresceine succinimidyl ester proliferation assay, ELISA, adaptive immune
modulation, cerebral autoregulation, and neuroimaging
methods (see Supplemental Digital Content 1, http://links.
lww.com/CCM/E238).
Statistics
The data obtained were assumed to be nonparametric and analyzed using GraphPad Prism software (San Diego, CA). KruskalWallis with uncorrected Dunn multiple comparisons test, two-way
analysis of variance with Fisher Least Significant Difference multiple comparison, Kolmogorov-Smirnov rank-sum test for organ
dysfunction, and Mann-Whitney U tests were used to compare
data by day and between cohorts. All tests were two-tailed, and
significance was set as p value of less than 0.05. Values presented in
text are mean ± sd. Spearman correlation analysis was used to correlate autoregulation and neuroimaging scores with absolute cell
counts and cytokines. This study was not adequately powered for
venoarterial ECMO subgroup analyses alone. One patient on day
1 and another on day 3 were identified as outliers and excluded
from the atypical lymphocyte differential analysis.

RESULTS
ECMO Patient Cohort
Within the ECMO patient cohort, three patients had a clinical change in neurologic examination, and an additional five
patients had neurologic injury identified by standard-of-care
post-ECMO MRI (Fig. 1; and Supplemental Table 1, Supplemental Digital Content 1, http://links.lww.com/CCM/E238).
An additional patient presented with infarcts prior to placement
www.ccmjournal.org
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Figure 1. Enrollment diagram. This diagram shows all enrollment for
this pilot study, including status/post (s/p) exclusion criteria. Patient
recruitment was determined a prior to be completed after 20 patients.
CPR = cardiopulmonary resuscitation, ECMO = extracorporeal membrane
oxygenation, PI = principal investigator, VA = venoarterial, VV = venovenous.

on ECMO. Together, these patients were identified as “acquired
brain injury” patients. Three patients with white matter injury
related to prematurity, and an additional eight patients without
neurologic deficits and/or neuroimaging abnormalities, were
identified as “no brain injury.” There was no difference in the partial thromboplastin time goals or heparin infusion in U/kg/d between patients with and without brain injury (Supplemental Fig.

1, Supplemental Digital Content 1, http://links.lww.com/CCM/
E238), although patients with brain injury presented with lower
anti-Xa levels and received more platelets (Supplemental Fig. 1,
C and D, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). There was also no difference in severity of organ dysfunction (kidney and liver) between ECMO cohorts (blood urea
nitrogen, creatine, aspartate amino transferase, alanine amino
transferase, and alkaline phosphatase). For all ECMO patients (n
= 20), we observed acute increases in plasma IL-6 and IL-8 (p
< 0.01) compared with disease-only patients (n = 5) (Fig. 2, A
and B), in accordance with previous results (5). Grouped analyses
using flow cytometry (Supplemental Fig. 2, Supplemental Digital
Content 1, http://links.lww.com/CCM/E238) revealed a trend toward an increase of peripheral CD4 T cell cellularity on day 3
of ECMO (p = 0.06) (Supplemental Fig. 3, Supplemental Digital Content 1, http://links.lww.com/CCM/E238) compared with
sick controls, as the only adaptive immune response. Concomitant analyses of innate cellularity revealed minimal elevation of
innate cell subsets in grouped ECMO-treated patients versus sick
control patients. Finally, we analyzed differential counts taken as
standard-of-care diagnostics, including pre-ECMO counts not
available for the flow cytometry analysis (Supplemental Fig. 4,
Supplemental Digital Content 1, http://links.lww.com/CCM/
E238). For neutrophil, lymphocyte, atypical lymphocyte, and
monocyte counts, only monocytes were elevated on day 3 compared with all other days (Supplemental Fig. 4D, Supplemental
Digital Content 1, http://links.lww.com/CCM/E238).

Figure 2. Cytokine levels are elevated in extracorporeal membrane oxygenation (ECMO) patients with acquired brain injury. ECMO induces early
cytokine up-regulation for (A) interleukin (IL)–6 and (B) IL-8 at day 1 of ECMO (n = 20) compared with disease-control patients without ECMO (n = 5).
Circle shapes are nonbrain injury patients, and triangles represent brain injury patients. C, Heat map representation of all mean ± sd values (text shown,
pg/mL) of cytokines separated by brain injury status. Significance is defined as *p < 0.05, **p < 0.01 by nonparametric Kruskal-Wallis analysis of variance
versus sick control shown in the far left column of the heat map.
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phenomenon that requires further investigation. Only B cells
increased interferon (IFN)–γ
production with brain-injured
plasma (p < 0.001) (Supplemental Fig. 5D, Supplemental
Digital Content 1, http://links.
lww.com/CCM/E238). These
data suggest that patients on
ECMO and experiencing brain
injury possess an environment
within their circulation that is
conducive to initiating an activated, pro-inflammatory adaptive immune response.
Noncanonical
Inflammatory Immune
Cells Are Elevated in
ECMO/Brain Injury
Patients
Figure 3. Plasma from brain-injured patients supported with extracorporeal membrane oxygenation
Surprisingly, during our leu(ECMO) drives healthy adaptive immune cells toward a pro-inflammatory phenotype. Black bar graphs show
+
kocyte survey, we came across
nonparametric Kruskal-Wallis analysis of variance results for triplicate experiments for activation status (CD25 ,
n = 6) of (A) CD4+ helper T cells, (B) CD8+ cytotoxic T cells, and (C) CD19+ B cells after exposure to healthy
adaptive immune cells that did
plasma-containing media (left columns, squares, n = 5), or ECMO patient-derived plasma-containing media
not express cardinal adaptive
from patients without brain injury (middle columns, circles, n = 2), or with brain injury (right columns, triangles,
immune cell markers. Rarely
n = 4). Permutations of test conditions resulted in 10 test conditions for control plasma, six for nonbrain injury
ECMO, and 13 for brain injury ECMO. Plasma from ECMO patients with brain injury also elevated intracellular
described, T cells expressing
interleukin (IL)–17 production in (D) helper T cells and (F) B cells, but not (E) cytotoxic T cells. Values are mean
CD161+ produce IL-17 and
± sd and significance between groups on an individual day is shown as *p < 0.05, **p < 0.01, ***p < 0.001, ****p
are
postulated to contribute
< 0.0001 versus healthy plasma unless otherwise indicated by brackets.
to immune-mediated neurologic diseases (11). Grouped
Plasma From ECMO/Brain-Injured Patients Drives
ECMO patients exhibited a decrease in cellularity of activated
Healthy Adaptive Immune Cells Toward a Pro(i.e., CD161+) helper T cells at day 1 (p < 0.05) and day 3
Inflammatory Phenotype
(p < 0.05) of ECMO (Supplemental Fig. 6, Supplemental DigWhen segregating patients according to the presence of brain
ital Content 1, http://links.lww.com/CCM/E238) compared
injury (Fig. 2C), the brain injury group exhibited greater elevawith sick controls. These populations were, however, elevated
tions in pro-inflammatory IL-6 on day 1 of ECMO (p < 0.01
in ECMO patients with brain injury, including activated B cells
vs sick control). The greatest response, however, came from (day 1; p < 0.05), natural killer T cells (day 3; p < 0.05 and day
the neutrophil chemotactic factor IL-8, which increased over 7; p < 0.001) and cytotoxic T cells (day 7; p < 0.05) compared
10-fold in brain-injured ECMO patients (p < 0.01 vs sick con- with ECMO patients without brain injury (Supplemental
trol) and continued to be elevated on day 3 (p < 0.05 vs sick Fig. 7, Supplemental Digital Content 1, http://links.lww.com/
control) and day 7 of ECMO. IL-8 promotes adaptive T helper CCM/E238). These patients with brain injury had concomi(Th) cell recruitment and activation of neutrophils, which fur- tant elevations in activated macrophages (Supplementary Fig.
ther drives the induction of pro-inflammatory Th1 and Th17
7F, Supplemental Digital Content 1, http://links.lww.com/
cells (10). We used peripheral plasma to indirectly ascertain in- CCM/E238) across the full course of ECMO. This shows that
duction of inflammatory adaptive immune cells and found that in patients presenting with acquired brain injury there is an
plasma from ECMO brain-injured patients activated helper increase in highly inflammatory circulating adaptive immune
(p < 0.001) and cytotoxic (p < 0.01) T cells and B cells (p < 0.01)
populations not identified in standard-of-care immune cell
(Fig. 3; and Supplemental Fig. 5, Supplemental Digital Con- differential counts (Supplemental Fig. 4 E–H, Supplemental
tent 1, http://links.lww.com/CCM/E238) compared with acti- Digital Content 1, http://links.lww.com/CCM/E238).
vation by plasma collected from ECMO patients without brain
injury or sick patient controls. Brain-injured ECMO-derived ECMO/Brain Injury Coincides With Increased CNSplasma also drove increased production of IL-17 in helper T Specific Autoreactive Cytotoxic T Cells
cells (p < 0.0001) and B cells (p < 0.001), with a concomitant CNS antigen presentation to, and subsequent activation of,
loss in IL-17-producing cytotoxic T cells in brain injury co- adaptive immune cells can lead to the induction of CNScultures relative to nonbrain injury (p = 0.05), an interesting
targeting adaptive immune responses (12–15), with these
Critical Care Medicine
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autoreactive adaptive immune responses sufficiently capable
of inducing brain injury, as seen in other CNS diseases (15, 16).
Thus, we determined if ECMO-treated patients exhibited
adaptive immune cell responses that target CNS-specific peptides, including myelin and neuronal peptides (Supplemental
Table 3, Supplemental Digital Content 1, http://links.lww.
com/CCM/E238) (12, 13, 15). All responses were compared
with an unstimulated sample response to control for the underlying generalized inflammatory disease state unique to each
patient (Supplemental Table 1, Supplemental Digital Content
1, http://links.lww.com/CCM/E238). We used banked samples
from sick PELOD-matched control patients (n = 4), ECMO
patients without brain injury (n = 9), and ECMO patients that
presented with acquired brain injury (n = 7).
CNS-targeted autoreactivity in helper T cells was similar in
magnitude between all cohorts (Fig. 4; and Supplemental Fig. 8,
Supplemental Digital Content 1, http://links.lww.com/CCM/
E238), although fewer patients with brain injury had autoreactive
cells (three out of seven patients, day 1 of ECMO) compared with
the non brain-injured ECMO cohort (eight out of eight patients)
(Fig. 4A). The magnitude of helper T cell autoreactivity significantly diminished in the brain-injured cohort over the course of
ECMO (day 1 vs day 7; p < 0.05), although day 7 is limited in patient
sample size, with only two patients in the acquired brain injury

cohort. In contrast, the magnitude of autoreactivity for cytotoxic
T cells in ECMO patients peaked at day 3 (p < 0.05 vs days 1 and
7) (Supplemental Fig. 7D, Supplemental Digital Content 1, http://
links.lww.com/CCM/E238), with a consistently higher magnitude
of autoreactivity in the brain-injured ECMO patients on both day 1
(p < 0.01) and day 3 (p < 0.05) of ECMO (Fig. 4B). Autoimmune
responses for cytotoxic T cells were not detectable at day 7
of ECMO. The cytotoxic T cell responses to both myelin and
neuronal peptides were driven by a smaller subset of patients
(~25–40% of patients), which was different from the helper T cell
response that often included autoreactivity in 60–100% of the
patients tested.
B cell autoreactivity was also much higher in the ECMOtreated patients over sick control patients (Supplemental Fig.
8F, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). When analyzed based on brain injury status,
B cell autoreactivity to CNS antigens is unique on day 1 of
ECMO, as it is significantly elevated in the ECMO patients
without brain injury (p < 0.01) (Fig. 4C). For the ECMO
patients without brain injury, this early and high level of CNSdirected autoreactivity significantly diminished at both day 3
(p < 0.001 vs day 1) and day 7 (p < 0.01 vs day 1) of ECMO. In
contrast, ECMO patients with brain injury exhibited a delayed
increase in autoreactivity on day 3 (p < 0.05). Although half
of the ECMO patients (4/8)
without brain injury exhibited
autoreactivity to myelin and
neuronal peptides on day 1, the
day 3 response in the brain injury cohort overall was driven
by the response in two patients.
In summary, ECMO treatment
coincided with autoreactivity
to CNS-specific antigens in cytotoxic T cell and B cells.

Figure 4. Brain injury associated with cytotoxic T cell autoreactivity to CNS antigens. Autoreactivity data
separated by brain injury were analyzed by two-way analysis of variance, Fisher Least Significant Difference.
Positive responses (change in proliferation fraction [ΔPF]) from all patients tested (#/#) and corresponding
% indicated below graph. A, CD4 helper T cell responses did not differ between extracorporeal membrane
oxygenation (ECMO) patients without brain injury (circles) and those with brain injury (triangles). B,
Autoreactive CD8 T cell responses were, however, more abundant in brain injury ECMO patients, and (C) B cell
autoreactivity was increased ECMO patients without brain injury at day 1, which was reversed by day 3 as braininjured ECMO patients exhibited increased autoreactivity. Significance between groups on an individual day is
shown as *p < 0.05, **p < 0.01, ***p < 0.001 or between groups, as indicated by brackets.

Disrupted Cerebral
Autoregulation Correlates
With Adaptive Immune
Responses for ECMO
Patients With Brain Injury
Pediatric patients on ECMO
exhibit disturbances in cerebral
autoregulation (17), which is
the brain’s ability to maintain
constant CBF despite changes
in systemic blood pressure (18).
Continuous near-infrared spectroscopy bedside monitoring
can identify disrupted cerebral
autoregulation for several diseases associated with secondary
neurologic injury, including
ECMO (17, 19, 20). In our patient population, 13 patients
were simultaneously enrolled in

e210
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an observational study to monitor cerebral autoregulation over
the course of ECMO, including six ECMO patients without brain
injury, and seven with acquired brain injury. Taking the value for
disrupted cerebral autoregulation for the duration of ECMO, we
determined correlations between disrupted cerebral autoregulation and circulating immune cells (Supplemental Table 4, Supplemental Digital Content 1, http://links.lww.com/CCM/E238).
Only the percentage of activated helper T cells consistently correlated with disrupted cerebral autoregulation over the course of
ECMO. Once data were parsed between ECMO patients with and
without brain injury (Table 1), the majority of significant correlations between adaptive immune cell subsets and disruptions in
cerebral autoregulation were driven by the brain-injured ECMO
patients. This shows that patients who exhibit disruptions in cerebral autoregulation experience concomitant activation of the
adaptive immune system.

DISCUSSION
ECMO is a complex technique used in cases where trauma,
sepsis, congenital heart disease, or respiratory failure necessitates cardiopulmonary support. There has been a steady increase
in pediatric ECMO usage (21, 22), but secondary complications
increase morbidity and mortality and include ischemic stroke,
intracranial hemorrhage, and seizures (23–25). For the first

time, we show in this pilot study that pediatric ECMO results
in the loss of cerebral autoregulation concomitant with a robust mobilization and activation of adaptive immune cells,
detection of CNS-targeting adaptive immune responses, and
induction of pro-inflammatory cell signaling predominantly in
patients that present with acquired brain injury. We previously
reported that acquired brain injuries could be predicted by loss
of cerebral autoregulation in pediatric ECMO patients (17).
What is critical to consider is that as cerebral autoregulation
is disrupted, the blood flow in the brain is no longer constant
but fluctuates similar to the systemic circulation. Subsequent
higher shear stress at the capillaries could disrupt the bloodbrain barrier, whereas lower shear stress within the venules
could increase the ability of circulating leukocytes to diapedese
into the parenchyma (26, 27). This is particularly relevant for
patients with high levels of circulating IL-8, which induces the
firm adherence of immune cells to the endothelial vessel walls
(28). Increased leukocyte diapedesis under the low-flow would
bring inflammatory (Fig. 2), activated (Fig. 3), and autoreactive (Fig. 4) adaptive immune cells into contact with the brain
parenchyma, a necessary step to further promote brain injury.
We observed a distinct cytotoxic T cell response in ECMO
patients with brain injury at days 1 and 3 of ECMO, with CNS
autoreactivity to myelin and neuronal peptides. These data

TABLE 1. Correlation of Adaptive Immune Responses to Disruption of Cerebral
Autoregulation While on Extracorporeal Membrane Oxygenation
ECMO Patients—No Injury
% (R2)
Leukocyte Population

ECMO Patients—Brain Injury
% (R2)

Day 1

Day 3

Day 7

Day 1

Day 3

Day 7

General leukocytes

(–) 0.31

(–) 0.03

(–) 0.18

0.70a

0.71a

0.86

T cells

(–) 0.06

0.12

(–) 0.43

(–) 0.24

(–) 0.22

B cells

(–) 0.48

(–) 0.03

(–) 0.01

0.01

(–) 0.31

Activated B cells

0.03

0.45

0.34

(–) 0.16

0.55

(–) 0.03

Helper T cells

0.10

0.17

0.009

(–) 0.58

(–) 0.56

(–) 0.96

Activated helper T cells

(–) 0.43

(–) 0.30

(–) 0.56

0.75

0.77

0.99c

Cytotoxic T cells

0.009

(–) 0.12

0.002

0.58a

0.54c

0.88

Activated cytotoxic T cells

(–) 0.04

(–) 0.02

0.09

0.002

0.26

0.99a

Natural killer T cells

0.55

(–) 0.008

0.19

0.43

0.26

0.70

Monocytes

0.04

(–) 0.04

(–) 0.53

(–) 0.16

(–) 0.10

0.65

Activated macrophages

0.0002

(–) 0.03

(–) 0.16

0.09

0.30

0.20

Dendritic cells

0.14

0.01

(–) 0.35

(–) 0.06

(–) 0.07

(–) 0.83

Natural killer cells

(–) 0.01

(–) 0.02

(–) 0.007

(–) 0.19

(–) 0.15

(–) 0.37

Granulocytes

(–) 0.98b

0.35

0.93

(–) 0.24

(–) 0.21

(–) 0.99c

(n = 5)

(n = 6)

(n = 3)

(n = 7)

(n = 7)

(n = 3)

Patient number

0.20
(–) 0.002

a

a

c

b

ECMO = extracorporeal membrane oxygenation, R2= R square goodness of fit, linear regression, % = percent immune population, (–) = negative slope in
correlation.
a
p < 0.05.
b
p < 0.01.
c
p < 0.06.
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are highly suggestive that cytotoxic T cells are being mobilized by the brain injury and not by the underlying disease,
and increased T cell egress may be reflected in lower circulating
T cell populations. In fact, the CNS targeting by these cells is
reminiscent of similar cells found in Rasmussen’s Encephalitis,
multiple sclerosis (MS), and the murine model of MS, which
have all implicated inflammatory CNS-specific cytotoxic T
cells as mediators of neuropathology (29). This is understandable, as the inflammatory nature of these cells would allow CNS
access, whereas their antigen-specificity would allow them to
target CNS resident cells (30). More in-depth experiments are
required to ascertain the role of ECMO-induced autoreactive
cytotoxic T cells, whose pathology may not ultimately be limited to the duration of ECMO or the underlying disease, but
could affect neurodevelopment with long-lasting detrimental
outcomes (3).
Surprisingly, we also detected a high number of CNSspecific B cells in the nonbrain injured group on day 1 of
ECMO. This phenomenon declined by day 3, just as autoreactive responses of B cells in brain-injured patients increased.
Autoreactivity by B cells contributes to several neurologic
diseases (14, 31, 32), with development of autoreactive CNSspecific B cells considered extremely dangerous, as these
cells are capable of 1) producing antibodies which target
CNS resident cells (33) and 2) generating de novo secondary
lymphoid tissue within the CNS (34). Thus, it was very surprising those ECMO patients without brain injury exhibited
a robust CNS-directed B cell autoreactivity. Although highly
speculative, it is possible that some self-reactive adaptive
immune cells play a neuroprotective or neuroreparative role
after brain injury. In fact, peripheral antigen presentation of
neuronal antigens in stroke patients correlates to improved
long-term recovery (35). Thus, we are mindful of the potential for CNS autoreactivity-mediated neuroprotection and
will dissect the role for each of these autoreactive cells in
future studies.
Before this study, there have been several drugs which target
inflammation, including glucocorticoids, and other immunemodulatory agents, with the goal of altering the inflammatory response preoperatively to prevent brain injury. Although
these drugs have been successfully used in preclinical studies,
clinical trials identified certain inadequacies of global immune
suppression in providing neuroprotection (36, 37). In pediatric
patients, altered CBF and induction of systemic inflammation
may be key mechanisms of brain injury, whereas inflammatory
mediators stemming from the adaptive system, either cellular
(T and B cells) or cytokines (IL-8, IL-6, IFN-γ, IL-17) can be
neurotoxic to the developing brain. Now, with the findings of
this study, we believe that a focused suppression of the adaptive immune system using pharmacologic agents approved in
other CNS diseases may have a potential neuroprotective role
for ECMO patients at risk of acquired brain injury (38).
This study had several limitations, including small patient enrollment and cerebral autoregulation measurements
that spanned the course of ECMO and not the specific times
of blood draw. We also recognize that the PELOD-matched
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control patients were not as sick as patients placed on ECMO.
Future studies should determine the long-term effects of systemic inflammation, including cytokine production, loss of
autoregulation, persistent CNS-directed autoreactivity, and
their cumulative associations with neurocognitive and other
developmental delays in this patient population. In addition,
in order to elucidate the mechanisms involved in the ECMOinduced neuro-immunological interactions, it must be determined if ECMO-activated adaptive immune cells can directly
target CNS resident cells.

CONCLUSIONS
This small observational study highlights a previously uncharacterized association between disruptions in cerebral autoregulation, either preceding or concomitant to neuroimmune
responses that may contribute to brain injury for pediatric
ECMO patients. As these patients experience developmental
delays for years after ECMO, it is critical to identify the role
of neuroinflammatory adaptive immune cell mechanisms that
target the developing CNS.
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